Pharmaceutical

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).

Jul 7, 2023 - 20:00
ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).
Read the original article

Tags:

Previous Article

MesoCancerVac by Amphera for Metastatic Pancreatic Cancer: Likelihood of Approval

Next Article

CC-95775 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about Moderna’s RSV vaccine, Aurobindo problems, and more

STAT+: Pharmalittle: We’re reading about Moderna’s RSV ...

Feb 13, 2024

STAT+: Health data breaches hit an all-time high in 2023

STAT+: Health data breaches hit an all-time high in 2023

Dec 25, 2023

STAT+: Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis

STAT+: Novo Nordisk is concluding research on Wegovy’s ...

Nov 5, 2023